未知生产厂商
T-cell engager targeting the cancer-specific glycoform of CD24 (neoCD24). Designed to address the limitations of existing immunotherapies by selectively targeting the tumor-specific epitope while redirecting T cells for potent anti-tumor activity, maximizing selectivity for tumor cells while minimizing the risk of on-target/off-tumor toxicity.
ONC-783 is being evaluated in ONC-783-001, a Phase 1 open-label, dose-escalation study in the United States to evaluate the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
